Juno Appoints Maggie Wilderotter To Board Of Directors

SEATTLE, Nov. 25, 2014 /PRNewswire-USNewswire/ -- Juno Therapeutics today announced that Maggie Wilderotter, Chairman and CEO of Frontier Communications Corporation, has been appointed to the Juno Board of Directors. 

Wilderotter, the eighth member of Juno's Board of Directors, brings significant public company experience as both a board member and a senior executive to the Juno Board. Before joining Frontier Communications in 2004, Wilderotter was Senior Vice President of Worldwide Public Sector at Microsoft. She has also held senior positions with Wink Communications, AT&T, and McCaw Cellular Communications. She serves on the boards of Xerox Corporation, Procter & Gamble Company, and a number of non-profit organizations.

"Maggie's management acumen and distinguished Board service make her a widely respected adviser, and we are delighted she is bringing her wise counsel to Juno's Board," said Juno CEO Hans Bishop.

Among other accolades, from 2009 through 2013 Wilderotter was ranked by FORTUNE magazine as one of the "50 Most Powerful Women in Business" and the Financial Times in 2011 named Wilderotter one of "The Top 50 Women in World Business."

"I look forward to working with Juno's board and management team to build on the company's successful first year.  The scientific discovery Juno is engaged in combined with a first class strategy to bring forward game changing therapies makes this a company I am privileged to be associated with," said Wilderotter.

Mrs. Wilderotter holds a bachelor's degree in economics from the College of the Holy Cross and was awarded an Honorary Doctor of Engineering degree, honoris causa, from the Stevens Institute of Technology.

About Juno
Juno Therapeutics, Inc. is building a fully integrated biopharmaceutical company focused on revolutionizing medicine by re-engaging the body's immune system to treat cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as solid tumors.  Several product candidates have shown compelling evidence of tumor shrinkage in the clinical trials in refractory leukemia and lymphoma conducted to date. The company's long-term aim is to improve and leverage its cell-based platform to develop new product candidates that address a broader range of cancers and human diseases.  Juno brings together innovative technologies from three of the world's leading research institutions – the Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, and Seattle Children's Research Institute.  

www.JunoTherapeutics.com

Logo - http://photos.prnewswire.com/prnh/20140113/DC45426LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/juno-appoints-maggie-wilderotter-to-board-of-directors-300000682.html

SOURCE Juno Therapeutics